IMNM

Immunome Stock Analysis

AI Rating

Low
  • Quality1/10
  • Growth↑ 6/10
  • Value↓ 0/10
Immunome sales and earnings growth
IMNM Growth
Good
  • Revenue Y/Y↓ -71.79%
  • EPS Y/Y↑ 25.16%
  • FCF Y/Y↓ -27.38%
Immunome gross and profit margin trends
IMNM Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -5593.80%
  • ROIC 5Y↓ -1625.97%
Immunome net debt vs free cash flow
IMNM Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Immunome stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks